Eagerly-anticipated data from an ongoing Phase I/II trial into epacadostat in combination with Keytruda (pembrolizumab) have been released, as the annual meeting of the American Society of Clinical Oncology (ASCO) continues in Chicago.
Data from the trial, which is investigating the dual therapy as a treatment for non-small cell lung cancer (NSCLC), showed an overall response rate (ORR) of 35%.
Epacadostat, under development by US-based Incyte (Nasdaq: INCY), is a selective oral inhibitor of the IDO1 enzyme that stops cancer cells from evading the immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze